These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 8808477)

  • 21. Vancomycin resistance: are there better glycopeptides coming?
    Linden PK
    Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria.
    Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F
    Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infective endocarditis and glycopeptides.
    Pittet D; Harding I
    J Infect; 1998 Sep; 37(2):127-35. PubMed ID: 9821086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [First case of infection due to vancomycin resistant Enterococcus faecalis in New Caledonia].
    Garin B; Barny S; Lechevallier S; Agathe-Nerine J
    Med Mal Infect; 2006 May; 36(5):297-8. PubMed ID: 16631333
    [No Abstract]   [Full Text] [Related]  

  • 25. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci].
    Pham Dang C; Gouin F; Touchais S; Richard C; Potel G
    Pathol Biol (Paris); 2001 Sep; 49(7):587-96. PubMed ID: 11642024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Glycopeptides (vancomycin, teicoplanin)].
    Furuta I; Kitahashi T
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():423-6. PubMed ID: 15658354
    [No Abstract]   [Full Text] [Related]  

  • 28. Teicoplanin or vancomycin in the treatment of gram-positive infections?
    Murphy S; Pinney RJ
    J Clin Pharm Ther; 1995 Feb; 20(1):5-11. PubMed ID: 7775615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High risk of cross-reactivity between vancomycin and sequential teicoplanin therapy.
    Hsiao SH; Chou CH; Lin WL; Lee EJ; Liao LH; Chang HJ; Yeh PY; Lin CY; Wu TJ
    J Clin Pharm Ther; 2012 Jun; 37(3):296-300. PubMed ID: 22017186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A closer look at vancomycin, teicoplanin, and antimicrobial resistance.
    Zeckel ML
    J Chemother; 1997 Oct; 9(5):311-31; discussion 332-5. PubMed ID: 9373787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zeckel ML. A closer look at vancomycin, teicoplanin and antimicrobial resistance. J Chemother 1997; 9: 311-335.
    Nathwani D
    J Chemother; 1998 Jun; 10(3):266-70. PubMed ID: 9669655
    [No Abstract]   [Full Text] [Related]  

  • 34. Safety and efficacy of glycopeptide antibiotics.
    Finch RG; Eliopoulos GM
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii5-13. PubMed ID: 15750036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Linezolid for the treatment of complicated skin and skin structure infections in children.
    Yogev R; Patterson LE; Kaplan SL; Adler S; Morfin MR; Martin A; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S172-7. PubMed ID: 14520143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Early switch from vancomycin to oral linezolid for treatment of gram-positive heart valve endocarditis.
    Colli A; Campodonico R; Gherli T
    Ann Thorac Surg; 2007 Jul; 84(1):87-91. PubMed ID: 17588391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study.
    Cepeda JA; Whitehouse T; Cooper B; Hails J; Jones K; Kwaku F; Taylor L; Hayman S; Shaw S; Kibbler C; Shulman R; Singer M; Wilson AP
    J Antimicrob Chemother; 2004 Feb; 53(2):345-55. PubMed ID: 14711840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The comparative efficacy and safety of teicoplanin and vancomycin.
    Cobo J; Fortún J
    J Antimicrob Chemother; 1996 Dec; 38(6):1113-4. PubMed ID: 9023665
    [No Abstract]   [Full Text] [Related]  

  • 39. Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and gram-positive bacteremia.
    Sidi V; Roilides E; Bibashi E; Gompakis N; Tsakiri A; Koliouskas D
    J Chemother; 2000 Aug; 12(4):326-31. PubMed ID: 10949982
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dalbavancin: a novel lipoglycopeptide antibacterial.
    Pope SD; Roecker AM
    Pharmacotherapy; 2006 Jul; 26(7):908-18. PubMed ID: 16803423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.